Since vaccination with this vaccine began, there have been “34 cases, including 11 deaths in total” of rare strokes that occurred in France, among the more than 4,068,000 injections made on May 6, the French Medicines Agency (ANSM).
These four new cases belong to two women in their 60s and 70s and two men in their 50s.
The complications observed related to cerebral venous thrombosis of two of them, visceral thrombosis (gastrointestinal tract, editor’s note) and deep vein thrombosis associated with pulmonary embolism, determined ANSM according to the XI Pharmacovigilance Report of this vaccine.
The characteristics of the reported cases remain similar to those of the last assessment with a higher mean age (mean 60.5 years) and affect both sexes approximately equally (18 women / 16 men).
The Health Agency states that as of March 19, 2021, the use of AstraZeneca’s Vaxzevria vaccine in France is reserved for people 55 years of age or older.
Use for this age group The Supreme Health Authority (HAS) recommended, on May 12, maintaining it, with an emphasis on the “indisputable benefit” of the vaccine.
French Health Minister Olivier Ferrand took over HAS for the opportunity to expand the use of this vaccine to all adults, despite the very rare risk of these atypical strokes.
If side effects persist for more than three days, such as dizziness, headache, visual disturbances, nausea / vomiting, shortness of breath, severe chest pain, stomach pain, and skin bruising (petechiae) away from the site injection, a doctor. it must be consulted immediately.